How to Prepare Overseas Registration Dossiers for Medical Dressings?

Preparing registration dossiers for overseas market authorization of medical dressings does not begin with compiling documents; it begins with determining whether the product falls within the scope of medical device regulation in the target country.

Published: 2026-08-28 19:22 | Updated: 2026-08-28 19:22

Key Summary

Companies should first confirm the classification of the medical dressing—for example, whether wound dressings or wound care products are regulated as medical devices—and then determine the risk class and registration pathway. Requirements for technical documentation, quality management systems, clinical evaluation, labeling, and local representation vary significantly from country to country; domestic registration dossiers cannot simply be copied. GHWP member states, as well as markets in Southeast Asia, the Middle East, and Latin America, generally accept ISO 13485 and the GHTF-based technical documentation framework, but localization conversion and corrective submissions are required. Companies should systematically assess the reusability of existing NMPA, CE, FDA, or MDSAP dossiers and then supplement validation reports, risk management documentation, and post-market surveillance plans according to target-country requirements. Common risks include misclassification, inappropriate selection of local agents, unclear control of certificates, and lack of responsibility for changes and renewals. It is recommended to complete a gap analysis and registration strategy assessment before starting the application to reduce the risk of repetitive document preparation and corrective actions.

For Chinese medical device companies, a more prudent approach is to first conduct product classification and dossier gap assessment, and then determine whether NMPA, CE, FDA, ISO 13485, or other market dossiers can be reused. Registration in the target market typically affects technical documentation, authorized representatives, importer cooperation, label language, quality management system evidence, and subsequent change maintenance. If the process is driven only by "which documents to submit," it is easy to encounter corrections or rework in model coverage, evidence-chain consistency, label claims, and certificate control. AIMEILI recommends that companies plan this issue within the context of GHWP member states and multi-country market access strategies, using one set of reusable core technical documents to support localization in different markets rather than recreating dossiers for each country.

Compiled based on AIMEILI's registration practice database, medical device international registration knowledge base, and public regulatory information; specific projects should be based on the latest requirements of the target country's regulatory authority and the product dossier basis.

Applicable Scenarios and Core Issues

Medical dressings are a common category in medical devices, but overseas registration document preparation is often simplified by companies as "translating domestic documents." In reality, regulatory logic, document formats, and evidence requirements vary significantly across target countries, and directly using domestic dossiers often leads to corrections or rejections. This article is intended for medical dressing manufacturers, registration responsible persons, and quality system responsible persons planning to enter overseas markets. It focuses on the core issues that must be resolved before starting registration and the judgment path that document preparation should follow.

Core issues include: whether the product is recognized as a medical device, what the classification and risk class are, whether the registration applicant is clear, what requirements existing documents can cover, which documents must be submitted by a local agent or authorized representative, and how the certificate holder can change and renew the certificate.

Registration Determination Logic

Step 1: Determine whether the product falls within the regulatory scope. If a medical dressing is only used to cover wounds and absorb exudate, it is usually classified as a medical device; however, some products, such as dressings containing drug components or dressings used for cosmetic repair, may be regulated as drugs or cosmetics. Companies should check item by item against the target country's laws and classification rules.

Step 2: Determine the risk class and registration pathway. The same medical dressing may be Class I, Class IIa, or Class II in different countries. Classification determines whether notified body review is required, whether self-declaration is allowed, and whether clinical data are required. Companies should prioritize a registration pathway supported by existing technical documentation.

Step 3: Assess reusability of existing NMPA, CE, FDA, or ISO 13485 dossiers. If the product is already registered domestically, the registration certificate, test reports, biocompatibility reports, etc., can serve as a foundation; but target-country requirements for labeling, language, test standards, and local agents must be re-confirmed.

Step 4: Confirm local regulatory requirements. This includes authorized representative or local agent, registration fees, language requirements for technical documentation, post-market surveillance, and vigilance systems. GHWP member states and markets in Southeast Asia, the Middle East, and Latin America generally refer to the GHTF documentation framework, but each country adds its own requirements and cannot be fully copied.

Dossiers and Evidence

Core dossiers for overseas registration of medical dressings typically include administrative documents, technical documents, and quality management system documents. Administrative documents include application forms, manufacturer authorization letters, agency agreements, and local agent information. Technical documents should cover product description, intended use, design verification, biocompatibility, sterilization validation, shelf life, and stability data. Quality management system documents should demonstrate compliance with ISO 13485 or other recognized standards. If the target country accepts MDSAP, MDSAP audit reports can be used to reduce duplicate audits. System documents must be controlled versions and valid; expired or invalid certificates will be directly rejected.

Clinical evaluation or clinical evidence: not all medical dressings require clinical trials. Low-risk products can be evaluated through literature, clinical experience data, or equivalence with a similar product, but equivalence must be demonstrated and comparison records retained. High-risk products or dressings containing drug components may require clinical data or additional testing.

Labeling must comply with target-country language and content requirements. For example, Middle Eastern countries may require Arabic, and Latin American countries require Spanish or Portuguese. The intended use, warnings, and precautions in labeling must be consistent with the registration file and must not contain unapproved claims.

Post-market surveillance documentation is increasingly important. Target countries require manufacturers to submit post-market surveillance plans, adverse event reporting pathways, complaint handling, and update mechanisms. These documents should be prepared in advance, not completed after registration.

For multi-country registration, companies should establish a core technical document library, organize reusable technical documents according to the GHTF framework, and generate localized versions for each country. This reduces repetitive work and manages changes and corrections centrally.

Common Mistakes

• Skipping product classification and directly choosing a registration pathway based on experience, leading to incorrect document types and reviewing bodies.
• Translating NMPA registration dossiers into English without adjusting to the target country's technical documentation format.
• Ignoring the regulatory responsibilities of the local agent or authorized representative, resulting in an inability to respond promptly to registration failures or changes.
• Submitting incomplete or expired quality management system certificates, causing rejection of the application.
• Labeling and instructions for use are not localized, language does not comply with requirements, or contains unapproved intended use claims.
• Failing to plan post-market surveillance and change management, leading to gaps in subsequent certificate maintenance.
• When registering the same product in multiple countries, repeatedly submitting different versions of documents, increasing the risk of corrections.

Company Preparation Checklist

• Confirm product classification and risk class according to target-country regulations and retain classification justification.
• Organize existing certificates and reports, including NMPA registration certificate, CE certificate, FDA certificate, ISO 13485, MDSAP, etc., and confirm validity.
• Prepare a technical document gap table against the target-country checklist, identifying tests and validation data that need to be supplemented.
• Identify a local agent or authorized representative and sign a formal agreement specifying scope of service and certificate control.
• Arrange translation and notarization of labels and instructions for use to ensure language and content compliance.
• Establish post-market surveillance and adverse event reporting processes, and prepare corresponding documents and record templates.
• Establish a registration project plan for each target country, setting milestones and responsible persons.

AIMEILI Regulatory Interpretation and Business Impact

Regulatory interpretation: The most common misjudgment in overseas registration of medical dressings lies in classification and registration pathway. Many companies assume that dressings are all low-risk and submit in the simplest manner; when additional clinical data or notified body involvement is required, the project timeline is significantly extended. We recommend that companies conduct a gap analysis early in the project, compare target-country regulatory requirements with existing dossiers item by item, and form a complete evidence-gap list. Do not start by hiring a translation company; first identify the validations and format adjustments that need to be supplemented.

Business impact: The reusable portions of the technical documentation include design verification, biocompatibility, sterilization validation, and risk management documents, but labeling, registration application forms, local agent information, and post-market surveillance plans must be localized according to local requirements. Certificate control and change/renewal responsibilities are core clauses in agency agreements; companies must clarify these with the local agent; otherwise, subsequent product changes or certificate transfers may create significant risk. In multi-country registration, we recommend building common technical documentation templates in GHTF format so that each country only needs to add country-specific information instead of starting from scratch. This approach reduces the probability of corrections and reduces duplicate internal work.

Frequently Asked Questions

Do medical dressings need to provide clinical data for overseas registration?

Not necessarily. Low-risk medical dressings can usually complete clinical evaluation through biocompatibility reports, equivalent product comparison, or literature data. However, if the product contains drug components, is used for deep wounds, or the intended use involves high-risk scenarios, the target country may require clinical trial data or additional safety evidence. Companies should assess in advance based on classification and intended use.

Can existing CE registration dossiers be directly used for GHWP member state registration?

No. The portions of CE dossiers that comply with EU regulations can serve as a technical basis, but GHWP member states have their own registration requirements and document formats. Commonly, local-language labeling, local agent authorization, specific test reports, and post-market surveillance documents need to be supplemented. Companies should treat CE dossiers as input, not as the final submission version.

What responsibilities does a local agent assume in overseas registration of medical dressings?

A local agent is generally responsible for communication with the regulatory authority, receiving official notifications, and assisting with submission of changes and renewals. In some countries, the local agent also serves as the certificate holder or co-applicant. The reliability of the agent, contract terms, and certificate control directly affect registration progress and subsequent certificate maintenance. Companies should verify the agent's qualifications and cooperation history before signing the contract.

Content Review and Applicability Boundary

Content author: AIMEILI Regulatory Editorial Department. Professional review: AIMEILI Medical Device International Registration Project Team. Source principle: Priority is given to official regulatory agencies, international organizations, standard organizations, and publicly available regulatory information; industry media and project experience are used only as auxiliary judgment. Applicability boundary: This article is for preliminary understanding, document preparation, and project planning, and does not replace the formal requirements of target-country regulatory authorities, test conclusions, or legal opinions.